201 related articles for article (PubMed ID: 16769612)
1. Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes.
Fialho SL; Rêgo MB; Siqueira RC; Jorge R; Haddad A; Rodrigues AL; Maia-Filho A; Silva-Cunha A
Curr Eye Res; 2006 Jun; 31(6):525-34. PubMed ID: 16769612
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and toxicity investigations of a new intraocular lens with a dexamethasone drug delivery system: a pilot study.
Siqueira RC; Filho ER; Fialho SL; Lucena LR; Filho AM; Haddad A; Jorge R; Scott IU; Cunha Ada S
Ophthalmologica; 2006; 220(5):338-42. PubMed ID: 16954713
[TBL] [Abstract][Full Text] [Related]
3. Poly-epsilon-caprolactone intravitreous devices: an in vivo study.
Silva-Cunha A; Fialho SL; Naud MC; Behar-Cohen F
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2312-8. PubMed ID: 19117927
[TBL] [Abstract][Full Text] [Related]
4. Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants in normal rabbit and pharmacodynamics in a rat model of choroidal neovascularization.
Robinson MR; Baffi J; Yuan P; Sung C; Byrnes G; Cox TA; Csaky KG
Exp Eye Res; 2002 Feb; 74(2):309-17. PubMed ID: 11950241
[TBL] [Abstract][Full Text] [Related]
5. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device.
Jaffe GJ; Yang CH; Guo H; Denny JP; Lima C; Ashton P
Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3569-75. PubMed ID: 11006254
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.
Chang-Lin JE; Burke JA; Peng Q; Lin T; Orilla WC; Ghosn CR; Zhang KM; Kuppermann BD; Robinson MR; Whitcup SM; Welty DF
Invest Ophthalmol Vis Sci; 2011 Jun; 52(7):4605-9. PubMed ID: 21421864
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant.
Chang-Lin JE; Attar M; Acheampong AA; Robinson MR; Whitcup SM; Kuppermann BD; Welty D
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):80-6. PubMed ID: 20702826
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits' eyes.
De Paiva MRB; Lage NA; Guerra MCA; Mol MPG; Ribeiro MCS; Fulgêncio GO; Gomes DA; Da Costa César I; Fialho SL; Silva-Cunha A
Doc Ophthalmol; 2019 Feb; 138(1):3-19. PubMed ID: 30456454
[TBL] [Abstract][Full Text] [Related]
9. Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye.
Sigurdsson HH; Konráethsdóttir F; Loftsson T; Stefánsson E
Acta Ophthalmol Scand; 2007 Sep; 85(6):598-602. PubMed ID: 17645424
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant.
Kato A; Kimura H; Okabe K; Okabe J; Kunou N; Ogura Y
Invest Ophthalmol Vis Sci; 2004 Jan; 45(1):238-44. PubMed ID: 14691179
[TBL] [Abstract][Full Text] [Related]
11. Biodegradable chitosan and polylactic acid-based intraocular micro-implant for sustained release of methotrexate into vitreous: analysis of pharmacokinetics and toxicity in rabbit eyes.
Manna S; Banerjee RK; Augsburger JJ; Al-Rjoub MF; Donnell A; Correa ZM
Graefes Arch Clin Exp Ophthalmol; 2015 Aug; 253(8):1297-305. PubMed ID: 25896109
[TBL] [Abstract][Full Text] [Related]
12. Ocular tissue distribution of betamethasone after anterior-episcleral, posterior-episcleral, and anterior-intrascleral placement of nonbiodegradable implants.
Okabe K; Kimura H; Okabe J; Ogura Y
Retina; 2007; 27(6):770-7. PubMed ID: 17621189
[TBL] [Abstract][Full Text] [Related]
13. Ocular safety profile and intraocular pharmacokinetics of an antagonist of EphB4/EphrinB2 signalling.
Brar M; Cheng L; Yuson R; Mojana F; Freeman WR; Gill PS
Br J Ophthalmol; 2010 Dec; 94(12):1668-73. PubMed ID: 20934994
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive evaluation of toxicity in vitreoretinal domain following insertion of sustained release methotrexate micro-implant.
Manna S; Caixeta Faraj RQ; Riemann B; Rao MB; Nair V; Riemann CD; Augsburger JJ; Correa ZM; Banerjee RK
Exp Eye Res; 2021 Apr; 205():108505. PubMed ID: 33617850
[TBL] [Abstract][Full Text] [Related]
15. Ocular pharmacokinetics of intravitreally administered brimonidine and dexamethasone in animal models with and without blood-retinal barrier breakdown.
Shen J; Durairaj C; Lin T; Liu Y; Burke J
Invest Ophthalmol Vis Sci; 2014 Feb; 55(2):1056-66. PubMed ID: 24448267
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the release profile and pharmacokinetics of intact and fragmented dexamethasone intravitreal implants in rabbit eyes.
Bhagat R; Zhang J; Farooq S; Li XY
J Ocul Pharmacol Ther; 2014 Dec; 30(10):854-8. PubMed ID: 25411827
[TBL] [Abstract][Full Text] [Related]
17. Release and velocity of micronized dexamethasone implants with an intravitreal drug delivery system: kinematic analysis with a high-speed camera.
Meyer CH; Klein A; Alten F; Liu Z; Stanzel BV; Helb HM; Brinkmann CK
Retina; 2012; 32(10):2133-40. PubMed ID: 23060033
[TBL] [Abstract][Full Text] [Related]
18. Effect of menthol on ocular drug delivery.
Xu X; Yu N; Bai Z; Xun Y; Jin D; Li Z; Cui H
Graefes Arch Clin Exp Ophthalmol; 2011 Oct; 249(10):1503-10. PubMed ID: 21597947
[TBL] [Abstract][Full Text] [Related]
19. Intraocular toxicity and pharmacokinetics of candesartan in a rabbit model.
Lee JE; Lim DW; Park HJ; Shin JH; Lee SM; Oum BS
Invest Ophthalmol Vis Sci; 2011 May; 52(6):2924-9. PubMed ID: 21228384
[TBL] [Abstract][Full Text] [Related]
20. Vitreoretinal toxicity of acetazolamide following intravitreal administration in the rabbit eye.
Borhani H; Rahimy MH; Peyman GA
Ophthalmic Surg; 1994 Mar; 25(3):166-9. PubMed ID: 8196921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
